FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.7  |  FHIR Version n/a  User: [n/a]

900000000000526001: REPLACED BY association reference set (foundation metadata concept)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module
900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)
900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)


14853 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
REPLACED BY association reference set (foundation metadata concept) Is a Historical association reference set (foundation metadata concept) true Inferred relationship Some

Members targetComponentId
Insulin zinc suspension (crystalline) adverse reaction Adverse reaction to zinc insulin
Insulin zinc suspension (crystalline) allergy Allergy to zinc insulin
Insulin zinc suspension adverse reaction Adverse reaction to zinc insulin
Intact parathyrin Parathyroid hormone
Intake process Introduction procedure (procedure)
Integrated musculoskeletal release Osteopathic combined treatment method (procedure)
Intellectual disability with cataract and kyphosis syndrome Congenital disorder of glycosylation type 1q (disorder)
Intentional X-ray contrast media overdose Intentional X-ray diagnostic contrast media overdose
Intentional X-ray contrast media poisoning Intentional X-ray diagnostic contrast media overdose
Intentional antabuse overdose Intentional disulfiram overdose (disorder)
Intentional antabuse poisoning Intentional disulfiram poisoning (disorder)
Intentional chlorprothixene overdose Intentional chlorprothixene overdose (disorder)
Intentional overdose by sodium valproate Intentional valproate overdose (disorder)
Intentional pesticide product overdose Intentional pesticide product poisoning
surdose intentionnelle de fusidate de sodium Intentional fusidic acid overdose
surdose intentionnelle de warfarine sodique Intentional warfarin overdose (disorder)
Intentional zuclopenthixol overdose Intentional chlorprothixene overdose (disorder)
Interdigital pilonidal sinus Barber's pilonidal sinus
Interferon alfa-2b 10million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 10million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 10million iu/mL injection solution 2.5mL vial Product containing precisely interferon alfa-2b 10 million unit/1 milliliter conventional release solution for injection (clinical drug)
Interferon alfa-2b 18 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 18million/iu solution Interferon alfa-2b only product
Interferon alfa-2b 18mu/vial Interferon alfa-2b only product
Interferon alfa-2b 25 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 3 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 30000000iu solution Interferon alfa-2b only product
Interferon alfa-2b 3million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 3million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 5 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 5million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 5million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 60million/iu solution Interferon alfa-2b only product
Interferon alfa-n3 human leu 5000000unt/mL injection solution 1mL vial Product containing precisely interferon alfa-n3 5 million unit/1 milliliter conventional release solution for injection (clinical drug)
Interferon beta-1a 12million iu/mL injection solution 0.5mL prefilled syringe Interferon beta-1a 30 microgram/mL solution for injection
Interferon beta-1a 24million iu/mL injection solution 0.5mL prefilled syringe Interferon beta-1a 24 million unit/mL solution for injection
Interferon beta-1a 30mcg/vial injection Product containing precisely interferon beta-1a 30 microgram/1 vial powder for conventional release solution for injection (clinical drug)
Interferon beta-1a 30mcg/vial injection solution Product containing precisely interferon beta-1a 30 microgram/1 vial powder for conventional release solution for injection (clinical drug)
Interferon beta-1a 6million iu powder and solvent for injection solution vial Interferon beta-1a only product in parenteral dose form
Interferon beta-1a 6million iu powder for injection solution vial Interferon beta-1a only product in parenteral dose form
Interferon beta-1b 100mcg injection solution Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
Interferon beta-1b 8million iu powder and solvent for injection solution vial Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
Interferon beta-1b 8million iu powder for injection solution vial Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
rapport provisoire Interim report (record artifact)
Intermediate factor VIII fraction 250iu powder and solvent for injection solution vial Coagulation factor VIII only product
Intermediate factor VIII fraction 500iu powder and solvent for injection solution vial Coagulation factor VIII only product
Intermediate lobe of right lung Structure of middle lobe of right lung (body structure)
Angiography of internal carotid arteries, bilateral Angiography of cervicocerebral arteries
Intermediate metabolizer due to cytochrome p450 CYP2C19 variant CYP2C19 intermediate metabolizer
Intermediate metabolizer due to cytochrome p450 CYP2D6 variant Cytochrome P450 family 2 subfamily D member 6 intermediate metabolizer (finding)
Intermittent continuous positive airway pressure Positive pressure ventilation
Intermittent positive pressure ventilation Positive pressure ventilation
Intermittent positive pressure ventilation Positive pressure ventilation
ventilation en pression positive intermittente par ballon et masque Positive pressure ventilation via bag and mask (regime/therapy)
ventilation en pression positive intermittente par tube endotrachéal Positive pressure ventilation via endotracheal tube
Internal fixation of mandible with arch bars External fixation of mandible with arch bars (procedure)
Internal fixation of mandible with arch bars External fixation of mandible with arch bars (procedure)
Internal granuloma of pulp Internal resorption of tooth
Internal migration Transuterine migration (finding)
Internal oblique flap Internal oblique muscle flap
Internal resorption of crown of tooth Internal resorption of tooth
Internal unsealed radiotherapy NOS Radionuclide therapy
Internal unsealed radiotherapy NOS Radionuclide therapy
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IA1 IA1
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IA2 IA2
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IB1 IB1
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IB2 IB2
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIA1 IIA1
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIA2 IIA2
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIB American Joint Committee on Cancer stage IIB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIIA American Joint Committee on Cancer stage IIIA (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIIB American Joint Committee on Cancer stage IIIB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IVA American Joint Committee on Cancer stage IVA (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IVB IVB
International Federation of Gynecology and Obstetrics cervical cancer stage 0 Carcinoma in situ of uterine cervix
International Federation of Gynecology and Obstetrics cervical cancer stage I I
International Federation of Gynecology and Obstetrics cervical cancer stage II American Joint Committee on Cancer stage II (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage III American Joint Committee on Cancer stage III (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage IV IV
International Federation of Gynecology and Obstetrics cervical cancer stage Ia IA
International Federation of Gynecology and Obstetrics cervical cancer stage Ib IB
International Federation of Gynecology and Obstetrics cervical cancer stage Ib occ IB
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IIIA American Joint Committee on Cancer stage IIIA (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IVA American Joint Committee on Cancer stage IVA (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IVB IVB
International Federation of Gynecology and Obstetrics endometrial cancer stage I I
International Federation of Gynecology and Obstetrics endometrial cancer stage I A IA
International Federation of Gynecology and Obstetrics endometrial cancer stage I B IB
International Federation of Gynecology and Obstetrics endometrial cancer stage II American Joint Committee on Cancer stage II (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage III American Joint Committee on Cancer stage III (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IIIB American Joint Committee on Cancer stage IIIB (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IIIC1 American Joint Committee on Cancer stage IIIC1 (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IIIC2 American Joint Committee on Cancer stage IIIC2 (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IV IV
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IA IA
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IB IB
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IIIA American Joint Committee on Cancer stage IIIA (qualifier value)
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IIIB American Joint Committee on Cancer stage IIIB (qualifier value)
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IVA American Joint Committee on Cancer stage IVA (qualifier value)
International Federation of Gynecology and Obstetrics vulvar carcinoma (FIGO VC) stage IVB IVB
International Federation of Gynecology and Obstetrics vulvar carcinoma stage I I

Start Previous Page 61 of 149 Next End


Reference Sets

Reference set descriptor

Back to Start